{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"No response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Partial response"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"title":"Very good partial response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}],"title":"Complete response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"title":"Not evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The maximum response to therapy will be determined by assessing the best reported response for each participant. Maximum response will be determined based on free light chain and paraprotein assessments by the National Amyloidosis Centre. The data will be reported using the response rates observed (complete, very good partial, partial, no response).","groups":[{"description":"All patients allocated to dose level 0 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set.","id":"OG000","title":"Dose Level 0- Safety Population"},{"description":"All patients allocated to dose level 1 that received at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set.","id":"OG001","title":"Dose Level 1- Safety Population"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Within 6 months","title":"Maximum Response Determined by Paraprotein and Free Light Chain Assessment.","type":"SECONDARY","unitOfMeasure":"Participants"}